Blood-CNS Barrier Impairment in ALS patients versus an animal model
about
Aquaporins in the Spinal CordCerebral hypoxia/ischemia selectively disrupts tight junctions complexes in stem cell-derived human brain microvascular endothelial cellsBlood biomarkers for amyotrophic lateral sclerosis: myth or reality?Identification and characterization of Nanobodies targeting the EphA4 receptor.Prostacyclin prevents pericyte loss and demyelination induced by lysophosphatidylcholine in the central nervous system.Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis.Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis.Anti-Sulfoglucuronosyl Paragloboside Antibody: A Potential Serologic Marker of Amyotrophic Lateral Sclerosis.Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis.Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapyThe blood-epididymis barrier and inflammationCord blood as a potential therapeutic for amyotrophic lateral sclerosis.Non-neuronal Cells in ALS: Role of Glial, Immune cells and Blood-CNS Barriers.Endothelial and Astrocytic Support by Human Bone Marrow Stem Cell Grafts into Symptomatic ALS Mice towards Blood-Spinal Cord Barrier RepairPotential new complication in drug therapy development for amyotrophic lateral sclerosis.Boundary Cap Neural Crest Stem Cells Promote Survival of Mutant SOD1 Motor Neurons.Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis.Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia.Cellular and molecular mechanisms of motor neuron death in amyotrophic lateral sclerosis: a perspective.Expression of the ALS-causing variant hSOD1(G93A) leads to an impaired integrity and altered regulation of claudin-5 expression in an in vitro blood-spinal cord barrier model.Cerebrospinal fluid from patients with amyotrophic lateral sclerosis inhibits sonic hedgehog function.Immunoglobulins G from Sera of Amyotrophic Lateral Sclerosis Patients Induce Oxidative Stress and Upregulation of Antioxidative System in BV-2 Microglial Cell Line.Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules.Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules.Potential Role of Humoral IL-6 Cytokine in Mediating Pro-Inflammatory Endothelial Cell Response in Amyotrophic Lateral Sclerosis.A transgenic zebrafish model for the in vivo study of the blood and choroid plexus brain barriers using claudin 5.Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.
P2860
Q28066783-37D858C4-80B6-4C1F-BC73-2AF33B339317Q28822276-8AA1102D-D563-46DE-97B1-BA9CA6C04660Q33767845-58833274-6445-4AC1-8C82-AE1669084147Q33882055-CECB3EA4-6BE3-4586-848F-29CDB639725AQ35561041-4CB3620E-4A85-4C69-87BE-BA83D24F3D13Q35779264-0AC4D82A-0E9A-43AA-B7FB-1D7E0387818BQ36378047-80546960-EEED-42B2-9075-070EE39AC42FQ36981069-26C1D1D0-6B38-4C98-9586-5E0CC848A68AQ37299274-81BEA7E9-9632-4183-9F66-54C5A4E68C6DQ37487611-481FEE6C-E2A0-4F90-8839-6F53F7FDBEB5Q38239646-0A916C26-4332-4A69-8A05-3C7C4866C38AQ38594314-960708A2-D992-4E46-B193-2256A2EC955BQ38690849-6B59D9E1-C269-4820-A937-30F3F4AB5AE4Q38701186-EB54E9A3-6B82-4D9F-92E3-F7AA852867C9Q38730523-AE482F76-AA71-4E04-A9B0-B537D81CC4CEQ38881707-104D96BF-828E-4589-A237-CBAC486831A5Q41009549-940C546F-E71A-4A70-807C-338953814CD7Q41231187-A8C4A841-607A-421A-B6F2-F0C64CB5DC8DQ41921231-824E4ECC-1551-45AF-9144-E56A4F37A8D0Q41959651-873DC195-B875-42F4-B876-86D88AEA513BQ42035651-99AA6ADA-AC44-416E-9622-C8928CE451A2Q42323404-417ACB9B-6852-4DE2-BC48-3D398019E67AQ46245616-C5CBA5AB-4E36-4A00-921A-CCAC3B4CF994Q47169869-D77FF40E-42BD-4B9E-BAAF-2D8D9660F331Q47193821-5BA6CAE6-C0C7-476C-B4E0-3879810B1EA2Q47829271-2F05D671-3E7D-4106-8C04-256A106DC824Q50044507-264492C7-F6FA-4856-9C43-8AD00179334AQ53512219-5AE0EC53-BE4B-4368-9462-D03E3A1DBD67
P2860
Blood-CNS Barrier Impairment in ALS patients versus an animal model
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@ast
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@en
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@nl
type
label
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@ast
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@en
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@nl
prefLabel
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@ast
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@en
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@nl
P2860
P3181
P356
P1476
Blood-CNS Barrier Impairment in ALS patients versus an animal model
@en
P2093
Paul R. Sanberg
Svitlana Garbuzova-Davis
P2860
P3181
P356
10.3389/FNCEL.2014.00021
P407
P577
2014-01-01T00:00:00Z